NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT06919666 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: NT219

Sponsor

University of Colorado, Denver

Collaborators

[object Object]